Efficacy and Tolerability of Adjunctive Brivaracetam in Patients with Focal-Onset Seizures on Specific Concomitant Antiseizure Medications : Pooled Analysis of Double-Blind, Placebo-Controlled Trials
© 2024. The Author(s)..
INTRODUCTION: This article aimed to assess the efficacy and tolerability of adjunctive brivaracetam (BRV) in adults with focal-onset seizures on specific concomitant antiseizure medications (ASMs) taken as part of their treatment regimen.
METHODS: This was a post hoc analysis of pooled data from double-blind, placebo-controlled trials (N01252/NCT00490035, N01253/NCT00464269, and N01358/NCT01261325) in patients with uncontrolled focal-onset seizures randomized to BRV (50-200 mg/day) or placebo on the most common concomitant ASMs at trial initiation.
RESULTS: Nine concomitant ASMs were analyzed: carbamazepine (CBZ), lamotrigine (LTG), valproate (VPA), oxcarbazepine (OXC), topiramate (TPM), phenytoin (PHT), lacosamide (LCM), clobazam (CLB), and phenobarbital (PHB). Reduction over placebo in focal-onset seizure frequency per 28 days with BRV ranged from 11.7% (concomitant OXC) to 33.5% (concomitant PHB). The median percentage reduction from baseline in focal-onset seizure frequency per 28 days ranged from 25.5% to 42.8% in patients on BRV (placebo 4.4-21.2%); 50% responder rates ranged from 31.9% to 44.9% in patients on BRV (placebo 11.4-25.2%). In patients on BRV, seizure freedom ranged from 1.4% (concomitant PHT) to 12.5% (concomitant LCM); seizure freedom ranged from 0% to 1.2% in patients on placebo. All efficacy endpoints analyzed were consistently numerically higher in patients on BRV versus placebo. The overall incidence of treatment-emergent adverse events (TEAEs) was generally similar across subgroups by specific concomitant ASMs in patients on BRV (range 60.8-74.5%) or placebo (range 53.8-66.7%). Drug-related TEAEs were numerically higher across all subgroups by concomitant ASM in patients on BRV (range 35.2-48.3%) versus placebo (range 23.9-37.1%). Discontinuations due to TEAEs ranged from 2.9% to 13.3% in patients on BRV and was 0-5.7% for patients taking placebo across subgroups.
CONCLUSION: BRV was efficacious and well tolerated regardless of the specific concomitant ASMs used as part of their treatment regimen. These data show that in patients with focal-onset seizures, BRV provides additional efficacy to a broad range of ASMs.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Advances in therapy - 41(2024), 4 vom: 01. März, Seite 1746-1758 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Moseley, Brian [VerfasserIn] |
---|
Links: |
---|
Themen: |
563KS2PQY5 |
---|
Anmerkungen: |
Date Completed 25.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s12325-024-02795-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368462056 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368462056 | ||
003 | DE-627 | ||
005 | 20240326235423.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240215s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12325-024-02795-z |2 doi | |
028 | 5 | 2 | |a pubmed24n1348.xml |
035 | |a (DE-627)NLM368462056 | ||
035 | |a (NLM)38356105 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Moseley, Brian |e verfasserin |4 aut | |
245 | 1 | 0 | |a Efficacy and Tolerability of Adjunctive Brivaracetam in Patients with Focal-Onset Seizures on Specific Concomitant Antiseizure Medications |b Pooled Analysis of Double-Blind, Placebo-Controlled Trials |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.03.2024 | ||
500 | |a Date Revised 26.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a INTRODUCTION: This article aimed to assess the efficacy and tolerability of adjunctive brivaracetam (BRV) in adults with focal-onset seizures on specific concomitant antiseizure medications (ASMs) taken as part of their treatment regimen | ||
520 | |a METHODS: This was a post hoc analysis of pooled data from double-blind, placebo-controlled trials (N01252/NCT00490035, N01253/NCT00464269, and N01358/NCT01261325) in patients with uncontrolled focal-onset seizures randomized to BRV (50-200 mg/day) or placebo on the most common concomitant ASMs at trial initiation | ||
520 | |a RESULTS: Nine concomitant ASMs were analyzed: carbamazepine (CBZ), lamotrigine (LTG), valproate (VPA), oxcarbazepine (OXC), topiramate (TPM), phenytoin (PHT), lacosamide (LCM), clobazam (CLB), and phenobarbital (PHB). Reduction over placebo in focal-onset seizure frequency per 28 days with BRV ranged from 11.7% (concomitant OXC) to 33.5% (concomitant PHB). The median percentage reduction from baseline in focal-onset seizure frequency per 28 days ranged from 25.5% to 42.8% in patients on BRV (placebo 4.4-21.2%); 50% responder rates ranged from 31.9% to 44.9% in patients on BRV (placebo 11.4-25.2%). In patients on BRV, seizure freedom ranged from 1.4% (concomitant PHT) to 12.5% (concomitant LCM); seizure freedom ranged from 0% to 1.2% in patients on placebo. All efficacy endpoints analyzed were consistently numerically higher in patients on BRV versus placebo. The overall incidence of treatment-emergent adverse events (TEAEs) was generally similar across subgroups by specific concomitant ASMs in patients on BRV (range 60.8-74.5%) or placebo (range 53.8-66.7%). Drug-related TEAEs were numerically higher across all subgroups by concomitant ASM in patients on BRV (range 35.2-48.3%) versus placebo (range 23.9-37.1%). Discontinuations due to TEAEs ranged from 2.9% to 13.3% in patients on BRV and was 0-5.7% for patients taking placebo across subgroups | ||
520 | |a CONCLUSION: BRV was efficacious and well tolerated regardless of the specific concomitant ASMs used as part of their treatment regimen. These data show that in patients with focal-onset seizures, BRV provides additional efficacy to a broad range of ASMs | ||
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Antiseizure medication | |
650 | 4 | |a Brivaracetam | |
650 | 4 | |a Efficacy | |
650 | 4 | |a Epilepsy | |
650 | 4 | |a Focal-onset seizures | |
650 | 4 | |a Tolerability | |
650 | 7 | |a brivaracetam |2 NLM | |
650 | 7 | |a U863JGG2IA |2 NLM | |
650 | 7 | |a Anticonvulsants |2 NLM | |
650 | 7 | |a Lacosamide |2 NLM | |
650 | 7 | |a 563KS2PQY5 |2 NLM | |
650 | 7 | |a Pyrrolidinones |2 NLM | |
700 | 1 | |a Bourikas, Dimitrios |e verfasserin |4 aut | |
700 | 1 | |a Dimova, Svetlana |e verfasserin |4 aut | |
700 | 1 | |a Elmoufti, Sami |e verfasserin |4 aut | |
700 | 1 | |a Borghs, Simon |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g 41(2024), 4 vom: 01. März, Seite 1746-1758 |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2024 |g number:4 |g day:01 |g month:03 |g pages:1746-1758 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-024-02795-z |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 41 |j 2024 |e 4 |b 01 |c 03 |h 1746-1758 |